In the latest trading session, 0.76 million Checkpoint Therapeutics Inc (NASDAQ:CKPT) shares changed hands as the company’s beta touched 1.33. With the company’s most recent per share price at $3.39 changed hands at -$0.36 or -9.47% at last look, the market valuation stands at $184.48M. CKPT’s current price is a discount, trading about -32.74% off its 52-week high of $4.50. The share price had its 52-week low at $1.38, which suggests the last value was 59.29% up since then. When we look at Checkpoint Therapeutics Inc’s average trading volume, we note the 10-day average is 3.68 million shares, with the 3-month average coming to 1.32 million.
Analysts gave the Checkpoint Therapeutics Inc (CKPT) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended CKPT as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Checkpoint Therapeutics Inc’s EPS for the current quarter is expected to be 0.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Checkpoint Therapeutics Inc (NASDAQ:CKPT) trade information
Instantly CKPT was in red as seen in intraday trades today. With action 0.15%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 48.25%, with the 5-day performance at 0.15% in the green. However, in the 30-day time frame, Checkpoint Therapeutics Inc (NASDAQ:CKPT) is -2.16% down. Looking at the short shares, we see there were 5.56 million shares sold at short interest cover period of 5.7 days.
Checkpoint Therapeutics Inc (CKPT) estimates and forecasts
Data shows that the Checkpoint Therapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 62.44% over the past 6 months, a 71.29% in annual growth rate that is considerably higher than the industry average of 17.20%. Year-over-year growth is forecast to reach -76.70% down from the last financial year.
Consensus estimates given by 3 financial analysts project the company’s revenue in the current quarter to hit an average of 10.33k. 1 analysts are of the opinion that Checkpoint Therapeutics Inc’s revenue for the current quarter will be 4.53M. The company’s revenue for the corresponding quarters a year ago was 6k. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 72.17%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 26.32%. The 2024 estimates are for Checkpoint Therapeutics Inc earnings to increase by 72.24%.
CKPT Dividends
Checkpoint Therapeutics Inc is expected to release its next quarterly earnings report in January.
Checkpoint Therapeutics Inc (NASDAQ:CKPT)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 15.52% of Checkpoint Therapeutics Inc shares while 13.91% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 16.47%.
